SOBI and Biogen report success with Alprolix as a treatment for Haemophilia B

Biogen Idec and Swedish Orphan Biovitrum AB presented new findings for their long-lasting recombinant factor IX candidate Alprolix for Haemophilia B at the XXIV International Society on Thrombosis and Haemostasis (ISTH) Congress in Amsterdam, The Netherlands. Three oral presentations showcase new data that reinforce the potential safety, efficacy and pharmacokinetic profile of Alprolix. The data highlight the consistency of results with Alprolix across patient types and favourable physician ratings of its efficacy in treating acute bleeding episodes and controlling bleeding during and after major surgery.

An evaluation of the treatment of acute bleeding episodes across the prophylaxis and episodic (on-demand) treatment arms of the phase III B-LONG study showed that more than 90% of bleeds were controlled with a single injection of Alprolix and more than 97% were controlled with two or fewer injections. Results from an analysis of the phase III B-LONG study showed that Alprolix consistently controlled bleeding during and after 14 major surgeries in 12 patients with Haemophilia B. Physicians reported high efficacy levels of Aprolix during surgery, with haemostasis (the stoppage of bleeding) rated as �excellent� for 13/14 surgeries and �good� for 1/14 surgeries. According to investigator analyses, the results were comparable to that for similar surgeries in people without haemophilia.